BioCryst PharmsUS09058V1035BCRXBCRX
Financials
Market Cap
$867.89M5Y beta
1.95EPS (TTM)
-$1.178Free Float
199.80MRevenue (TTM)
$331.41MEBITDA (TTM)
-$102.05MFree Cashflow (TTM)
-$97.31MPricing
Analyst Ratings
The price target is $13.82 and the stock is covered by 12 analysts.
Buy
9
Hold
3
Sell
0
Information
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.